Published: 2021-11-22

Discarded old antibiotics as a new arsenal for multi-resistant isolates in diabetic foot ulcer infections: therapeutic value of parenteral colistin versus multi-resistant Pseudomonas species isolate strains: case report

Ahmed Shabhay, Jaffu O. Chilonga, Stephen E. Mshana, Zarina Shabhay, Jeff Van Baal, Anande Salewi, Theresia Mwakyembe, Florida Muro, Kondo Chilonga, David Msuya, Samwel Chugulu, Pius Horumpende


Antimicrobial resistance to current novel antibiotics is posing a major threat to both human and zoonotic life. In the absence of new novel antibiotics molecules, clinicians have resorted into a desperate last resort to review and re-introduce prior discarded antibiotics as their new weaponry in the fight against multi-resistant gram negative bacteria. We reported a case of a 77 year old bed ridden diabetic and hypertensive with renal impairment diagnosed with bilateral lower limbs wet gangrene. She underwent transfemoral on her right and transtibial amputation on her left lower limb. She developed surgical site infection on her right stump and wet gangrene on her left stump. Pus swab on her right stump revealed carbapenem resistant strains of Pseudomonas aeruginosa. She was instituted on parenteral colistin and showed no bacterial growth 7 days post treatment. She suffered an ischaemic cerebral vaso-occlusive stroke during her hospital stay. CT angiography of lower lung fields showed a large filling defect in the right main pulmonary artery extending to the lower lobe branches suggestive of right-sided pulmonary embolism. Our patient succumbed from her co-morbidities. Despite our patient succumbing to her multiple co-morbidities we reported this case to highlight the isolation of carbapenem resistant strains of P. aeruginosa and the efficacy and safety of colistin as a salvage antibiotic in renal impaired patients. Colistin can be safely used as a last reserve antibiotic for multi-resistant strains of P. aeruginosa infection even in patients with renal impairment.


Colistin, P. aeruginosa, Amputation, Case report

Full Text:



Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. 2006;6:589-601.

Ramesh N, Prasanth M, Ramkumar S, Suresh M, Tamhankar AJ, Gothandam KM, et al. Colistin susceptibility of gram-negative clinical isolates from Tamil Nadu, India. Asian Biomed. 2016;10(1):35-9.

Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol. 2014;5:1-15.

Javan AO, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71(7):801-10.

Azimi L, Lari AR. Colistin-resistant Pseudomonas aeruginosa clinical strains with defective biofilm formation. GMS Hyg Infect Control. 2019;14:12.

Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infective Ther. 2012;10:917-34.

Falagas ME, Grammatikos AP, Michalopoulos A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther. 2008;6(5):593-600.

Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect. 2008;14(9):816-27.

Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect. 2012;18(1):18-29.

Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37(1):177-92.

Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43-8.

Sivanmaliappan TS, Sevanan M. Antimicrobial susceptibility patterns of pseudomonas aeruginosa from diabetes patients with foot ulcers. Int J Microbiol. 2011;2011.

Jackson N, Czaplewski L, Piddock LJV. Discovery and development of new antibacterial drugs: Learning from experience? J Antimicrob Chemother. 2018;73(6):1452-9.

Mwanza S, Joshi S, Nambozi M, Chileshe J, Malunga P, Kabuya JBB, et al. The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia. Malar J. 2016;15(1):1-6.

Dunai A, Spohn R, Farkas Z, Lázár V, Györkei, Apjok G, et al. Rapid decline of bacterial drug-resistance in an antibiotic-free environment through phenotypic reversion. Elife. 2019;8:1-20.

Barbosa TM, Levy SB. The impact of antibiotic use on resistance development and persistence. Drug Resist Updat. 2000;3(5):303-11.